Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice
Open Access
- 18 January 2022
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (1) , e0140021
Abstract
Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection.Keywords
Funding Information
- HHS | National Institutes of Health (R01AI132374)
This publication has 24 references indexed in Scilit:
- NTM drug discovery: status, gaps and the way forwardDrug Discovery Today, 2018
- Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit RatesFrontiers in Microbiology, 2017
- Rifabutin Is Active against Mycobacterium abscessus ComplexAntimicrobial Agents and Chemotherapy, 2017
- Draft Genome Sequence of Mycobacterium abscessus BambooMicrobiology Resource Announcements, 2017
- DNA Replication in Mycobacterium tuberculosisMicrobiology Spectrum, 2017
- Targeting DnaN for tuberculosis therapy using novel griselimycinsScience, 2015
- Essential roles for imuA ′- and imuB -encoded accessory factors in DnaE2-dependent mutagenesis in Mycobacterium tuberculosisProceedings of the National Academy of Sciences, 2010
- A Novel Gene,erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates ofMycobacterium abscessusbut Is Absent fromMycobacterium chelonaeAntimicrobial Agents and Chemotherapy, 2009
- [Structure of griselimycin, polypeptide antibiotic extracted from streptomyces cultures. II. Structure of griselimycin].1971
- [Experimental antituberculous action of a new antibiotic: RP 11,072].1965